China Meheco's wholly-owned subsidiary, Tianfang Pharmaceutical, has received the approval notification for the marketing application of ezetimibe chemical active pharmaceutical ingredient from the National Medical Products Administration. This API is mainly used for primary hypercholesterolemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. The company stated that this approval will further expand its product portfolio and improve the layout of cardiovascular APIs. However, drug sales are subject to national policies and market conditions, and there are uncertainties. Investors are reminded to be aware of the risks.
China Meheco Co LtdSubsidiary received marketing approval for ezetimibe API from NMPA, expanding product portfolio.